Bayer’s Stivarga OK’d for Colon Cancer

(MedPage Today) -- Regorafenib (Stivarga), an inhibitor of multiple kinase enzymes, has been approved for use in treatment-refractory, metastatic colorectal cancer, the FDA announced Wednesday.

Post a Comment

Comments are closed.

Bayer’s Stivarga OK’d for Colon Cancer

(MedPage Today) — Regorafenib (Stivarga), an inhibitor of multiple kinase enzymes, has been approved for use in treatment-refractory, metastatic colorectal cancer, the FDA announced Thursday.

Post a Comment

Comments are closed.